Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Post Hoc Evaluation of Durvalumab Combined with Chemotherapy in Patients with Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial

  • By

  • Do-Youn Oh

  • Aiwu Ruth He

  • Shukui Qin

  • Li-Tzong Chen

  • Takuji Okusaka

  • Rebecca Griffin

  • Julie Wang

  • Ioannis Xynos

  • Arndt Vogel

  • Juan W. Valle

  • September 1, 2026

Share

  • 1

    Durvalumab combined with gemcitabine and cisplatin significantly improved overall survival in advanced biliary tract cancer compared to placebo plus GemCis.

  • 2

    The median overall survival was 13.0 months for durvalumab plus GemCis versus 11.4 months for placebo plus GemCis, with a hazard ratio of 0.75.

  • 3

    At 48 months, overall survival rates were 11.8% for durvalumab plus GemCis and 4.3% for placebo plus GemCis, indicating sustained benefit.

  • 4

    Subsequent anticancer therapy use was similar between treatment arms, with cytotoxic chemotherapy being the predominant follow-up treatment.

  • 5

    The TOPAZ-1 trial represents the longest follow-up for an immunotherapy plus chemotherapy regimen in first-line advanced biliary tract cancer.

Original Source(s)

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized

  • by Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Rebecca Griffin, Julie Wang, Ioannis Xynos, Arndt Vogel, Juan W. Valle

  • September 1, 2026

Related Content

AI-Designed Binder Improves CAR T Cell Activity in Mice

Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

  • September 15, 2026

  • 3 min
Musings from The Power List: Dajun Yang

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

  • September 15, 2026

  • 5 min
Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women